3 results
Approved WMOPending
The HOPE-3 trial will evaluate the effects of lipid modification with rosuvastatin and of blood pressure lowering with candesartan/hydrochlorothiazide (HCT) and their combination in a wide range of middle aged people, who are at average risk for…
Approved WMORecruiting
To determine the efficacy of treatment with mitapivat compared with placebo, as assessed by the reduction in transfusion burden in pediatric subjects with pyruvate kinase deficiency (PK deficiency) who are regularly transfused.
Approved WMORecruiting
To determine the efficacy of treatment with mitapivat compared with placebo, as assessed by the increase in Hb concentrations in pediatric subjects with PK deficiency who are not regularly transfused